(Photo credit: Brunswick Group)
Brunswick Group has appointed Xi Qing (pictured left) and Pru Bennett (pictured right) as partners.
Joining as a partner in Shanghai with a focus on the healthcare and life sciences sector, Xi most recently worked for Pfizer as vice president of government affairs, market access and communications, overseeing the full scope of corporate affairs activities for Pfizer’s established brands business in China.
“I am excited to join the growing team at Brunswick in China and look forward to strengthening the firm’s healthcare and life sciences capabilities in Asia," said Xi.
Xi has more than 20 years of experience in communications, market access, government affairs, crisis management and corporate social responsibility at multinational companies. He spent the last 16 years at Pfizer China, where he held several senior roles. In his last position at Pfizer, he led a team of 80 people to support Pfizer’s business and operations in China, overseeing central and local government affairs, corporate communications, brand communications, and pricing and market access.
Prior to Pfizer, Xi worked at Intel supporting communications across China.
As for Bennett, she is now a partner with a focus on corporate governance, having been a senior advisor of Brunswick Gorup since May 2019.
Prior to Brunswick, she was managing director of BlackRock and head of BlackRock’s investment stewardship team for APAC. At BlackRockthe asset management firm, she led a team responsible for engagement and proxy voting activities in relation to the companies in which BlackRock invests on behalf of clients.
“I am thrilled to deepen my contribution to Brunswick by becoming a Partner. I look forward to continuing to work closely with colleagues across Asia to advise the senior management teams and boards of clients on a range of governance issues," said Bennett.
Speaking of these appointments, Neal Wolin, CEO of Brunswick Group, commented, "Asia continues to be a critical region for Brunswick. Both Xi and Bennent add significant weight to our capabilities in healthcare and life sciences and corporate governance, respectively, and will put Brunswick in an even stronger position to capitalise on growth opportunities in the region.”